is currently the President & CEO of Searchlight Pharma Inc., a Canadian-based specialty pharmaceutical company focused on the acquisition and commercialization of innovative and unique healthcare and pharmaceutical products. Prior to joining Searchlight Pharma, Mark spent over 11 years building out the commercial and geographic footprint of Paladin Labs Inc., having served until September 2014 as Executive Vice President, Business and Corporate Development, followed by an independent international consulting mandate with Endo International PLC until February 2015. Mark joined Paladin in September 2003 and held responsibility for all business, corporate and product development activities at Paladin, a leading Canadian specialty pharmaceutical company. During his over 11-year tenure at Paladin, Mark concluded over 80 business development transactions spanning product in and out licensing, all variety of product partnership transactions, product acquisitions, and corporate M&A deals. From his arrival at Paladin in 2003, consolidated revenues grew from about $20 million to almost $270 million annually and Paladin’s share price rose from approximately $5 to a peak of $151 per share at the time of Paladin’s acquisition by Endo Healthcare Solutions. Prior to joining Paladin, Mark held progressively senior leadership positions at Pharmacia, a global top 10 pharmaceutical company that is now part of Pfizer Inc. While at Pharmacia, Mr. Nawacki specialized in the cardiology and pain therapeutic areas, and was responsible for Canadian business development initiatives.